MUC1-based recombinant Bacillus Calmette-Guerin vaccines as candidates for breast cancer immunotherapy

Expert Opinion on Biological Therapy

Volumn 10, Issue 7, 2010, Pages 1037-1048

  Yuan, Shifang ^a   Shi, Changhong ^b   Liu, Li ^b   Han, Wei ^b  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Breast cancer; Immunotherapy; MUC1; RBCG vaccine

Indexed keywords

B7 ANTIGEN; BCG VACCINE; DENDRITIC CELL VACCINE; DNA VACCINE; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOTOXIN; INTERLEUKIN 2; MANNAN; MUCIN 1; OVALBUMIN; POLYLYSINE; THERATOPE; VIRUS VECTOR;

ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CELLULAR IMMUNITY; CLINICAL TRIAL; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; DELAYED HYPERSENSITIVITY; DRUG SAFETY; DRUG TARGETING; HUMAN; HUMORAL IMMUNITY; IMMUNOSTIMULATION; IN VIVO STUDY; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; REVIEW; T LYMPHOCYTE; TREATMENT OUTCOME; TUMOR IMMUNITY; TUMOR VOLUME; VACCINIA VIRUS; VIRAL GENE DELIVERY SYSTEM;

ANIMALS; BCG VACCINE; BREAST NEOPLASMS; CANCER VACCINES; FEMALE; HUMANS; IMMUNOTHERAPY; MUCIN-1; MYCOBACTERIUM BOVIS; TREATMENT OUTCOME; VACCINES, SYNTHETIC;

MYCOBACTERIUM BOVIS BCG;

EID: 77953354606     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.2010.485185     Document Type: Review

References (135)

1. Shumway NM, Ibrahim N, Ponniah S, et al. Therapeutic breast cancer vaccines: a new strategy for early-stage disease. BioDrugs 2009;23:277-287
2. Huber CH, Wolfel T. Immunotherapy of cancer: from vision to standard clinical practice. J Cancer Res Clin Oncol 2004;130:367-374
3. Emens LA, Reilly RT, Jafee EM. Augmenting the potency of breast cancer vaccines: combined modality immunotharapy. Breast Dis 2009;3:13-24
4. Singh R, Bandyopadhyay D. MUC1: a target molecule for cancer therapy. Cancer Biol Ther 2007;6:481-486
5. Taylor-Papadimitriou J, Burchell J, Miles DW, et al. MUC1 and cancer. Biochim Biophys Acta 1999;1455:301-313
6. Saito H, Dubsky P, Dantin C, et al. Cross-priming of cyclin B1, MUC-1 and survivin-specific CD8+ T cells by dendritic cells loaded with killed allogeneic breast cancer cells. Breast Cancer Res 2006;8(6):R65
7. Baldus SE, Engelmann K, Hanisch FG. MUC1 and the MUCs: a family of human mucins with impact in cancer biology. Crit Rev Clin Lab Sci 2004;41:189-231
8. Zhang S, Graeber LA, Helling F, et al. Augmenting the immunogenicity of synthetic MUC1 peptide vaccines in mice. Cancer Res 1996;56:3315-3319
9. Hanisch FG. Design of a MUC1-based cancer vaccine. Biochem Soc Trans 2005;33:705-708
10. Huo Y, Li B, Zhang Y, et al. Pre-clinical safety evaluation of heat shock protein 65-MUC1 peptide fusion protein. Regul Toxicol Pharmacol 2007;49:63-74
11. Mushenkova N, Moiseeva E, Chaadaeva A, et al. Antitumor effect of double immunization of mice with mucin 1 and its coding DNA. Anticancer Res 2005;25:3893-3898
12. Yang E, Hu XF, Xing PX. Advances of MUC1 as a target for breast cancer immunotherapy. Histol Histopathol 2007;22:905-922
13. Koido S, Kashiwaba M, Chen D, et al. Induction of antitumor immunity by vaccination of dendritic cells transfected with MUC1 RNA. J Immunol 2000;165:5713-5719
14. Rosenblatt J, Kufe D, Avigan D. Dendritic cell fusion vaccines for cancer immunotherapy. Expert Opin Biol Ther 2005;5:703-715
15. Tanaka Y, Koido S, Chen D, et al. Vaccination with allogeneic dendritic cells fused to carcinoma cells induces antitumor immunity in MUC1 transgenic mice. Clin Immunol 2001;101:192-200
16. Graham RA, Burchell JM, Beverley P, et al. Intramuscular immunisation with MUC1 cDNA can protect C57 mice challenged with MUC1-expressing syngeneic mouse tumour cells. Int J Cancer 1996;65:664-670
17. Chu Y, Xia M, Lin Y, et al. Th2-dominated antitumor immunity induced by DNA immunization with the genes coding for a basal core peptide PDTRP and GM-CSF. Cancer Gene Ther 2006;13:510-519
18. Johnen H, Kulbe H, Pecher G. Long-term tumor growth suppression in mice immunized with naked DNA of the human tumor antigen mucin (MUC1). Cancer Immunol Immunother 2001;50:356-360
19. Barletta RG, Snapper B, Cirillo JD, et al. Recombinant BCG as a candidate oral vaccine vector. Res Microbiol 1990;141:931-939
20. Stover CK, de la Cruz VF, Fuerst TR, et al. New use of BCG for recombinant vaccines. Nature 1991;351:456-460
21. Hanson MS, Bansal GP, Langermann S, et al. Efficacy and safety of live recombinant BCG vaccines. Dev Biol Stand 1995;84:229-236
22. Chambers MA, Williams A, Gavier-Widen D, et al. Identification of a Mycobacterium bovis BCG auxotrophic mutant that protects guinea pigs against M. bovis and hematogenous spread of Mycobacterium tuberculosis without sensitization to tuberculin. Infect Immun 2000;68:7094-7099
23. Hernà ndez-Pando R, Castañòn M, Espitia C, et al. Recombinant BCG vaccine candidates. Curr Mol Med 2007;7:365-372
24. Tang CK, Apostolopoulos V. Strategies used for MUC1 immunotherapy: preclinical studies. Expert Rev Vaccines 2008;7:951-962
25. Feuerer M, Beckhove P, Bai L, et al. Therapy of human tumors in NOD/ SCID mice with patient-derived reactivated memory T cells from bone marrow. Nat Med 2001;7:452-458 (Pubitemid 32298548)
26. Brossart P, Heinrich KS, Stuhler G, et al. Identification of HLA-A2-restricted T-cell epitopes derived from the MUC1 tumor antigen for broadly applicable vaccine therapies. Blood 1999;93:4309-4317
27. Correa I, Plunkett T, Coleman J, et al. Responses of human T cells to peptides flanking the tandem repeat and overlapping the signal sequence of MUC1. Int J Cancer 2005;115:760-768
28. Tarp MA, Clausen H. Mucin-type O-glycosylation and its potential use in drug and vaccine development. Biochim Biophys Acta 2008;1780:546-563
29. Stepensky D, Tzehoval E, Vadai E, et al. O-glycosylated versus non-glycosylated MUC1-derived peptides as potential targets for cytotoxic immunotherapy of carcinoma. Clin Exp Immunol 2006;143:139-149
30. Dziadek S, Griesinger C, Kunz H, et al. Synthesis and structural model of an ? (2,6)-sialyl-T glycosylated MUC1 eicosapeptide under physiological conditions. Chemistry 2006;12:4981-4993
31. Westerlind U, Schroder H, Alexandra Hobel, et al. Tumor-associated MUC1 tandem-repeat glycopeptide microarrays to evaluate serum- and monoclonal-antibody specificity. Angew Chem Int Ed 2009;48:8263-8267
32. Taylor PJ, Burchell JM, Plunkett T, et al. MUC1 and the immunobiology of cancer. J Mammary Gland Biol Neoplasia 2002;7:209-221
33. Apostolopoulos V, McKenzie IF. Cellular mucins: targets for immunotherapy. Crit Rev Immunol 1994;14:293-309
34. Domschke C, Schuetz F, Ge Y, et al. Intratumoral cytokines and tumor cell biology determine spontaneous breast cancer-specific immune responses and their correlation to prognosis. Cancer Res 2009;69:8420-8428
35. Apostolopoulos V, Hu XF, Pouniotis DS, et al. MUC1: a molecule of many talents. Curr Trends Immunol 2003;12:629-639
36. Apostolopoulos V, McKenzie IF, Pietersz GA. Breast cancer immunotherapy: current status and future prospects. Immunol Cell Biol 1996;74:457-464
37. Apostolopoulos V, Pietersz GA, McKenzie IF. MUC1 and breast cancer. Curr Opin Mol Ther 1999;1:98-103
38. Kaiser A, Gaidzik N, Westerlind U, et al. A synthetic vaccine consisting of a tumor-associated sialyl-TN-MUC1 tandem-repeat glycopeptide and tetanus toxoid: induction of a strong and highly selective immune response. Angew Chem Int Ed Engl 2009;48:7551-7555
39. Kotera Y, Fontenot JD, Pecher G, et al. Humoral immunity against a tandem repeat epitope of human mucin MUC-1 in sera from breast, pancreatic, and colon cancer patients. Cancer Res 1994;54:2856-2860
40. Tarp MA, Sorensen AL, Mandel U, et al. Identification of a novel cancer-specific immunodominant glycopeptide epitope in the MUC1 tandem repeat. Glycobiology 2007;17:197-209
41. Chen D, Xia J, Tanaka Y, et al. Immunotherapy of spontaneous mammary carcinoma with fusions of dendritic cells and mucin 1-positive carcinoma cells. Immunology 2003;109:300-307
42. Kohlgraf KG, Gawron AJ, Higashi M, et al. Tumor-specific immunity in MUC1. Tg mice induced by immunization with peptide vaccines from the cytoplasmatic tail of CD227 (MUC1). Cancer Immunol Immunother 2004;53:1068-1084
43. Finn OJ, Jerome KR, Henderson RA, et al. MUC-1 epithelial tumor mucin-based immunity and cancer vaccines. Immunol Rev 1995;145:61-89
44. Acres B, Limacher JM. MUC1 as a target antigen for cancer immunotherapy. Expert Rev Vaccines 2005;4:493-502
45. Vlad AM, Kettel JC, Alajez NM, et al. MUC1 immunobiology: from discovery to clinical applications. Adv Immunol 2004;82:249-293
46. Soares MM, Mehta V, Finn OJ. Three different vaccines based on the 140-amino acid MUC1 peptide with seven tandemly repeated tumorspecific epitopes elicit distinct immune effector mechanisms in wild-type versus MUC1-transgenic mice with different potential for tumor rejection. J Immunol 2001;166:6555-6563
47. Goydos JS, Elder E, Whiteside TL, et al. A Phase I trial of a synthetic mucin peptide vaccine. Induction of specific immune reactivity in patients with adenocarcinoma. J Surg Res 1996;63:298-304
48. Reddish MA, MacLean GD, Koganty RR, et al. Anti-MUC1 class I restricted CTLs in metastatic breast cancer patients immunized with a synthetic MUC1 peptide. Int J Cancer 1998;76:817-823
49. Adluri S, Gilewski T, Zhang S, et al. Specificity analysis of sera from breast cancer patients vaccinated with MUC1-KLH plus QS-21. Br J Cancer 1999;79:1806-1812
50. Apostolopoulos V, Pietersz GA, McKenzie IFC. Cell-mediated immune response to MUC-1 fusion protein coupled to mannan. Vaccine 1996;14:930-938
51. Apostolopoulos V, Loveland BE, Pietersz GA, et al. CTL in mice immunized with human mucin 1 are MHC-restricted. J Immunol 1995;155:5089-5094
52. Apostolopoulos V, Pietersz GA, McKenzia IFC. Oxidative/reductive conjugation of mannan to antigen selects for T1 or T2 immune response. Proc Natl Acad Sci 1995;92:10128-10132
53. Karanikas V, Hwang LA, Pearson J. Antibody and T-cell responses of patients with adenocarcinoma immunized with mann-MUC-1 fusion protein. J Clin Invest 1997;100:2783-2790
54. Apostolopoulos V, Pietersz GA, Tsibanis A, et al. Pilot Phase III immunotherapy study in early-stage breast cancer patients using oxidized mannan-MUC1 [ISRCTN71711835]. Breast Cancer Res 2006;8:R27
55. Musselli C, Ragupathi G, Gilewski T, et al. Reevaluation of the cellular immune response in breast cancer patients vaccinated with MUC1. Int J Cancer 2002;97:660-667
56. Gilewski T, Adluri S, Ragupathi G. Vaccination of high risk breast cancer patients with MUC-1 keyhole limpet hemocyanin conjugate plus QS-21. Clin Cancer Res 2000;6:1693-1701
57. Mukherjee P, Madsen CS, Ginardi AR, et al. Mucin 1-specific immunotherapy in a mouse model of spontaneous breast cancer. J Immunother 2003;26:47-62
58. Ryan SO, Vlad AM, Islam K, et al. Tumor-associated MUC1 glycopeptide epitopes are not subject to self-tolerance and improve responses to MUC1 peptide epitopes in MUC1 transgenic mice. Biol Chem 2009;390:611-618
59. Plunkett T, Graham R, Correa I, et al. Protection against MUC1 expressing mouse tumours by intra-muscular injection of MUC1 cDNA requires functional CD8+ and CD4+ T cells but does not require the MUC1 tandem repeat domain. Int J Cancer 2004;109:691-697
60. Snyder LA, Goletz TJ, Gunn GR, et al. A MUC1/IL-18 DNA vaccine induces anti-tumor immunity and increased survival in MUC1 transgenic mice. Vaccine 2006;24:3340-3352
61. Jeon YH, Choi Y, Kim HJ, et al. Human sodium iodide symporter gene adjunctive radiotherapy to enhance the preventive effect of hMUC1 DNA vaccine. Int J Cancer 2007;121:1593-1599
62. Scholl SM, Balloul JM, Le GG, et al. Recombinant vaccinia virus encoding human MUC1 and IL2 as immunotherapy in patients with breast cancer. J Immunother 2000;23:570-580
63. Liu M, Acres B, Balloul JM, et al. Gene-based vaccines and immunotherapeutics. Proc Natl Acad Sci USA 2004;101(Suppl 2):14567-14571
64. Zhang S, Zhang H, Shi H, et al. Induction of immune response and anti-tumor activities in mice with a DNA vaccine encoding human mucin 1 variable-number tandem repeats. Hum Immunol 2008;69:250-258
65. Tang CK, Sheng KC, Pouniotis D, et al. Oxidized and reduced mannan mediated MUC1 DNA immunization induce effective anti-tumor responses. Vaccine 2008;26:3827-3834
66. Gong J, Avigan D, Chen D, et al. Activation of antitumor cytotoxic T lymphocytes by fusions of human dendritic cells and breast carcinoma cells. Proc Natl Acad Sci USA 1998;97:2715-2718
67. Gong J, Apostolopoulos V, Chen D, et al. Selection and characterization of MUC1-specific CD8+ T cells from MUC1 transgenic mice immunized with dendritic-carcinoma fusion cells. Immunology 2000;101:316-324
68. Gong J, Chen D, Kashiwaba M, et al. Induction of antitumor activity by immunization with fusions of dendritic and carcinoma cells. Nat Med 1997;3:558-561 (Pubitemid 27198656)
69. Gong J, Chen D, Kashiwaba M, et al. Reversal of tolerance to human MUC1 antigen in MUC1 transgenic mice immunized with fusions of dendritic and carcinoma cells. Proc Natl Acad Sci USA 1998;95:6279-6283
70. Maruyama K, Akiyama Y, Nara-Ashizawa N, et al. Adenovirus-mediated MUC1 gene transduction into human blood-derived dendritic cells. J Immunother 2001;24:345-353
71. Pecher G, Haring A, Kaiser L, et al. Mucin gene (MUC1) transfected dendritic cells as vaccine: results of a Phase I/II clinical trial. Cancer Immunol Immunother 2002;51:669-673
72. Sheng KC, Pietersz GA, Wright MD, et al. Dendritic cells: activation and maturation - applications for cancer immunotherapy. Curr Med Chem 2005;12:1783-1800
73. Kontani K, Taguchi O, Ozaki Y, et al. Dendritic cell vaccine immunotherapy of cancer targeting MUC1 mucin. Int J Mol Med 2003;12:493-502
74. Yang H, Cho NH, Seong SY. The Tat-conjugated N-terminal region of mucin antigen 1 (MUC1) induces protective immunity against MUC1-expressing tumours. Clin Exp Immunol 2009;158:174-185
75. Brossart P, Wirths S, Stuhler G, et al. Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells. Blood 2000;96:3102-3108
76. Loveland BE, Zhao A, White S, et al. Mannan-MUC1-pulsed dendritic cell immunotherapy: a Phase I trial in patients with adenocarcinoma. Clin Cancer Res 2006;12:869-877
77. Osada T, Clay TM, Woo CY, et al. Dendritic cell-based immunotherapy. Int Rev Immunol 2006;25:377-413
78. Tatsumi T, Storkus WJ. Dendritic cell-based vaccines and therapies for cancer. Expert Opin Biol Ther 2002;2:919-928
79. Fay JW, Palucka AK, Paczesny S, et al. Long-term outcomes in patients with metastatic melanoma vaccinated with melanoma peptide-pulsed CD34+ progenitor-derived dendritic cells. Cancer Immunol Immunother 2006;55:1209-1218
80. Avichezer D, Springer GF, Schechter B, et al. Immunoreactivities of polyclonal and monoclonal anti-T and anti-Tn antibodies with human carcinoma cells, grown in vitro and in a xenograft model. Int J Cancer 1997;72:119-127
81. Springer GF. Immunoreactive T and Tn epitopes in cancer diagnosis, prognosis, and immunotherapy. J Mol Med 1997;75:594-602
82. Longenecker BM, Reddish M, Koganty R, et al. Immune responses of mice and human breast cancer patients following immunization with synthetic sialyl-Tn conjugated to KLH plus detox adjuvant. Ann NY Acad Sci 1993;690:276-291
83. Miles DW, Towlson KE, Graham R, et al. A randomised Phase II study of sialyl-Tn and DETOX-B adjuvant with or without cyclophosphamide pretreatment for the active specific immunotherapy of breast cancer. Br J Cancer 1996;74:1292-1296
84. Sandmaier BM, Oparin DV, Holmberg LA, et al. Evidence of a cellular immune response against sialyl-Tn in breast and ovarian cancer patients after high-dose chemotherapy, stem cell rescue, and immunization with Theratope STn- KLH cancer vaccine. J Immunother 1999;22:54-66
85. Holmberg LA, Oparin DV, Gooley T, et al. The role of cancer vaccines following autologous stem cell rescue in breast and ovarian cancer patients: experience with the STn-KLH vaccine (Theratope). Clin Breast Cancer 2003;3(Suppl 4):S144-51
86. Acres B, Apostolopoulos V, Balloul JM, et al. MUC1-specific immune responses in human MUC1 transgenic mice immunized with various human MUC1 vaccines. Cancer Immunol Immunother 2000;48:588-594
87. Rochlitz C, Figlin R, Squiban P, et al. Phase I immunotherapy with a modified vaccinia virus (MVA) expressing human MUC1 as antigen-specific immunotherapy in patients with MUC1-positive advanced cancer. J Gene Med 2003;5:690-699
88. Acres B, Bonnefoy JY. Clinical development of MVA-based therapeutic cancer vaccines. Expert Rev Vaccines 2008;7:889-893
89. Harrop R, Carroll MW. Viral vectors for cancer immunotherapy. Front Biosci 2006;11:804-817
90. Gulley JL, Arlen PM, Tsang KY, et al. Pilot study of vaccination with recombinant CEA-MUC-1-TRICOM poxviral-based vaccines in patients with metastatic carcinoma. Clin Cancer Res 2008;14:3060-3069
91. Acres B. Cancer immunotherapy: Phase II clinical studies with TG4010 (MVA-MUC1-IL2). J BUON 2007;12(Suppl 1):S71-5
92. Singh R, Samant U, Hyland S, et al. Target specific cytotoxic activity of recombinant immunotoxin scFv (MUC1)- ETA on breast carcinoma cells and primary breast tumors. Mol Cancer Ther 2007;6:562-569
93. Danielczyk A, Stahn R, Faulstich D, et al. PankoMab: a potent new generation anti-tumour MUC1 antibody. Cancer Immunol Immunother 2006;55:1337-1347
94. Brennan MJ, Morris SL, Sizemore CF. Tuberculosis vaccine development: research, regulatory and clinical strategies. Expert Opin Biol Ther 2004;4:1493-1504
95. Ohara N and Yamada T. Recombinant BCG vaccines. Vaccine 2001;19:4089-4098
96. Shi C, Yuan S, Zhang H, et al. Cell-mediated immune responses and protective efficacy against infection with Mycobacterium tuberculosis induced by Hsp65 and hIL-2 fusion protein in mice. Scand J Immunol 2009;69(2):140-149
97. Colditz GA, Brewer TF, Berkey CS, et al. Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature. JAMA 1994;271:698-702
98. Jacobs WR Jr, Tuckman M, Bloom BR. Introduction of foreign DNA into mycobacteria using a shuttle phasmid. Nature 1987;327(6122):532-535
99. Dai W, Huang H, Yuan Y, et al. Novel vaccination strategies based on recombinant Mycobacterium bovis BCG. Int J Med Microbiol 2003;292:441-451
100. Liu W, O'Donnell MA, Chen X, et al. Recombinant bacillus Calmette-Guérin (BCG) expressing interferon-alpha 2B enhances human mononuclear cell cytotoxicity against bladder cancer cell lines in vitro. Cancer Immunol Immunother 2009;58:1647-1655
101. Chade DC, Borra RC, Nascimento IP, et al. Immunomodulatory effects of recombinant BCG expressing pertussis toxin on TNF-alpha and IL-10 in a bladder cancer model. J Exp Clin Cancer Res 2008;27:78
102. Dennehy M, Williamson AL. Factors influencing the immune response to foreign antigen expressed in recombinant BCG vaccines. Vaccine 2005;23:1209-1224
103. Wang Q, Li J, Zhang X, et al. Protective immunity of recombinant Mycobacterium bovis BCG expressing rhomboid gene against Eimeria tenella challenge. Vet Parasitol 2009;160:198-203
104. Aldovini A, Young RA. Humoral and cell-mediated immune responses to live recombinant BCG-HIV vaccine. Nature 1992;351:479-482
105. Ryan AA, Nambiar JK, Wozniak TM, et al. Antigen load governs the differential priming of CD8 T cells in response to the bacille Calmette-Guérin vaccine or Mycobacterium tuberculosis infection. J Immunol 2009;182:7172-7177
106. Kremer L, Dupre L, Riveau G, et al. Systemic and mucosal immune responses after intranasal administration of recombinant Mycobacterium bovis bacillus Calmette-Guerin expressing glutathione S-transferase from Schistosoma haematobium. Infect Immun 1998;66:5669-5676
107. Walker KB, Brennan MJ, Ho MM, et al. The second Geneva Consensus: recommendations for novel live TB vaccines. Vaccine 2010;28(11):2259-2270
108. Miyaji EN, Mazzantini RP, Dias WO, et al. Induction of neutralizing antibodies against diphtheria toxin by priming with recombinant Mycobacterium bovis BCG expressing CRM(197), a mutant diphtheria toxin. Infect Immun 2001;69:869-874
109. Luo Y, Chen X, Han R, et al. Recombinant bacille Calmette-Guerin (BCG) expressing human interferon-alpha 2B demonstrates enhanced immunogenicity. Clin Exp Immunol 2001;123:264-270
110. Biet F, Kremer L, Wolowczuk I, et al. Mycobacterium bovis BCG producing interleukin-18 increases antigen-specific gamma interferon production in mice. Infect Immun 2002;70:6549-6557
111. Orme IM. Preclinical testing of new vaccines for tuberculosis: a comprehensive review. Vaccine 2006;24:2-19
112. Berthet F, Lagranderie M, Gounon P, et al. Attenuation of virulence by disruption of the Mycobacterium tuberculosis erp gene. Science 1998;282:759-762 (Pubitemid 28489391)
113. Power CA,Wei G, Bretscher PA. Mycobacterial dose defines the Th1/ Th2 nature of the immune response independently of whether immunization is administered by the intravenous subcutaneous or intradermal route. Infect Immun 1998;66:5743-5750
114. Pym AS, Brodin P, Majlessi L, et al. Recombinant BCG exporting ESAT-6 confers enhanced protection against tuberculosis. Nat Med 2003;9:533-539
115. Grode L, Kursar M, Fensterle J, et al. Cell-mediated immunity induced by recombinant Mycobacterium bovis Bacille Calmette-Guérin strains against an intracellular bacterial pathogen: importance of antigen secretion or membrane-targeted antigen display as lipoprotein for vaccine efficacy. J Immunol 2002;168:1869-1876
116. Young S, O'Donnell M, Lockhart E, et al. Manipulation of immune responses to Mycobacterium bovis by vaccination with IL-2- and IL-18-secreting recombinant Bacillus Calmette Guerin. Immunol Cell Biol 2002;80:209-215
117. O'Donnell MA, Aldovini A, Duda RB, et al. Recombinant Mycobacterium bovis BCG secreting functional interleukin-2 enhances gamma interferon production by splenocytes. Infect Immun 1994;62:2508-2514
118. Andrade PM, Chade DC, Borra RC, et al. The therapeutic potential of recombinant BCG expressing the antigen S1PT in the intravesical treatment of bladder cancer. Urol Oncol 2009. [Epub ahead of print]
119. Arnold J, de Boer EC, O'Donnell MA, et al. Immunotherapy of experimental bladder cancer with recombinant BCG expressing interferon-? J Immunother 2004;27:116-123
120. Old LJ, Clarke DA, Benacerraf B. Effect of Bacillus Calmette-Guerin infection on transplanted tumours in the mouse. Nature 1959;184(Suppl 5):291-292
121. Luo Y, Yamada H, Chen X, et al. Recombinant Mycobacterium bovis bacillus Calmette-Guérin (BCG) expressing mouse IL-18 augments Th1 immunity and macrophage cytotoxicity. Clin Exp Immunol 2004;137:24-34
122. Luo Y, Yamada H, Evanoff DP, et al. Role of Th1-stimulating cytokines in bacillus Calmette-Guérin (BCG)-induced macrophage cytotoxicity against mouse bladder cancer MBT-2 cells. Clin Exp Immunol 2006;146:181-188
123. Herr HW, Morales A. History of Bacillus Calmette-Guerin and bladder cancer: an immunotherapy success story. J Urol 2008;179:53-56
124. Duda RB, Yang H, Dooley DD, et al. Recombinant BCG therapy suppresses melanoma tumor growth. Ann Surg Oncol 1995;2:542-549
125. Coley WB. The treatment of malignant tumors by repeated inoculations of erysipelas. With a report of ten original cases. Clin Orthop 1991;262:3-11
126. Nagorsen D, Marincola FM, Kaiser HE. Bacteria-related spontaneous and therapeutic remission of human malignancies. In Vivo 2002;16:551-556
127. Early Breast Cancer Trialists Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. Lancet 1992;339:71-85
128. Wiseman CL. Inflammatory breast cancer: 10-year follow-up of a trial of surgery, chemotherapy, and allogeneic tumor cell/BCG immunotherapy. Cancer Invest 1995;13:267-271
129. He J, Shen D, O'Donnell MA, et al. Induction of MUC1-specific cellular immunity by a recombinant BCG expressing human MUC1 and secreting IL2. Int J Oncol 2002;20:1305-1311
130. Chung MA, Luo Y, O'Donnell M, et al. Development and preclinical evaluation of a Bacillus Calmette-Guerin-MUC1-based novel breast cancer vaccine. Cancer Res 2003;63:1280-1287
131. Yuan S, Shi C, Han W, et al. Effective anti-tumor responses induced by recombinant Bacillus Calmette-Guérin vaccines based on different tandem repeats of MUC1 and GM-CSF. Eur J Cancer Prev 2009;18:416-423
132. Yuan S, Shi C, Lv Y, et al. A novel Bacillus Calmette-Guérin-based breast cancer vaccine that co-express multiple tandem repeats of MUC1 and CD80 breaks the immune tolerance and inhibits MUC1-positive breast cancer growth. Cancer Biother Radiopharm 2009;24:607-613
133. Lollini PL, De Giovanni C, Pannellini T, et al. Cancer immunoprevention. Future Oncol 2005;1:57-66
134. Hunter CA, Reiner SL. Cytokines and T cells in host defense. Curr Opin Immunol 2000;12:413-418
135. Emens LA, Asquith JM, Leatherman JM, et al. Timed sequential treatment with cyclophosphamide, doxorubicin, and an allogeneic granulocyte-macrophage colony-stimulating factor-secreting breast tumor vaccine: a chemotherapy dose-ranging factorial study of safety and immune activation. J Clin Oncol 2009;27:5911-5918